Lifesci Capital Has Positive Outlook of OLMA FY2025 Earnings

Olema Pharmaceuticals, Inc. (NASDAQ:OLMA) – Investment analysts at Lifesci Capital upped their FY2025 earnings per share (EPS) estimates for shares of Olema Pharmaceuticals in a research note issued on Wednesday, December 10th. Lifesci Capital analyst S. Slutsky now forecasts that the company will post earnings per share of ($1.83) for the year, up from their previous forecast of ($1.86). The consensus estimate for Olema Pharmaceuticals’ current full-year earnings is ($2.33) per share. Lifesci Capital also issued estimates for Olema Pharmaceuticals’ Q4 2025 earnings at ($0.47) EPS.

Olema Pharmaceuticals (NASDAQ:OLMA) last released its earnings results on Monday, November 10th. The company reported ($0.49) earnings per share for the quarter, missing the consensus estimate of ($0.44) by ($0.05).

A number of other analysts also recently issued reports on OLMA. HC Wainwright increased their price target on shares of Olema Pharmaceuticals from $36.00 to $45.00 and gave the stock a “buy” rating in a report on Thursday, December 11th. The Goldman Sachs Group raised their price target on shares of Olema Pharmaceuticals from $26.00 to $38.00 and gave the stock a “buy” rating in a research note on Thursday, December 11th. Oppenheimer boosted their target price on shares of Olema Pharmaceuticals from $45.00 to $48.00 and gave the company an “outperform” rating in a report on Thursday, December 11th. Zacks Research raised Olema Pharmaceuticals from a “strong sell” rating to a “hold” rating in a research report on Tuesday, September 9th. Finally, UBS Group reaffirmed a “buy” rating on shares of Olema Pharmaceuticals in a research note on Monday, October 20th. Seven research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average target price of $40.50.

Olema Pharmaceuticals Trading Up 8.4%

OLMA opened at $35.83 on Monday. The stock has a fifty day moving average price of $16.23 and a 200-day moving average price of $9.47. The company has a current ratio of 8.03, a quick ratio of 8.03 and a debt-to-equity ratio of 0.01. Olema Pharmaceuticals has a 12 month low of $2.86 and a 12 month high of $36.13. The firm has a market cap of $2.46 billion, a price-to-earnings ratio of -19.16 and a beta of 1.85.

Hedge Funds Weigh In On Olema Pharmaceuticals

A number of institutional investors have recently modified their holdings of OLMA. Ameritas Investment Partners Inc. boosted its stake in Olema Pharmaceuticals by 55.4% in the 2nd quarter. Ameritas Investment Partners Inc. now owns 6,080 shares of the company’s stock worth $26,000 after buying an additional 2,168 shares during the last quarter. ProShare Advisors LLC raised its stake in shares of Olema Pharmaceuticals by 21.1% during the second quarter. ProShare Advisors LLC now owns 14,766 shares of the company’s stock valued at $63,000 after purchasing an additional 2,569 shares during the period. Bank of America Corp DE increased its stake in Olema Pharmaceuticals by 0.4% during the 3rd quarter. Bank of America Corp DE now owns 802,304 shares of the company’s stock worth $7,855,000 after buying an additional 2,802 shares during the period. FNY Investment Advisers LLC lifted its stake in shares of Olema Pharmaceuticals by 100.0% in the second quarter. FNY Investment Advisers LLC now owns 10,000 shares of the company’s stock worth $42,000 after acquiring an additional 5,000 shares in the last quarter. Finally, Russell Investments Group Ltd. acquired a new stake in shares of Olema Pharmaceuticals during the third quarter worth approximately $53,000. Institutional investors and hedge funds own 91.78% of the company’s stock.

Insider Activity

In related news, Director Cyrus Harmon sold 10,000 shares of the business’s stock in a transaction dated Thursday, September 18th. The shares were sold at an average price of $8.33, for a total value of $83,300.00. Following the sale, the director directly owned 744,140 shares in the company, valued at $6,198,686.20. The trade was a 1.33% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. 16.36% of the stock is owned by company insiders.

Olema Pharmaceuticals Company Profile

Olema Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies for women’s cancers. Its lead product candidate is OP-1250, an estrogen receptor (ER) antagonist and a selective ER degrader, which is in Phase 3 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive, human epidermal growth factor receptor 2-negative breast cancer; and OP-1250 combine with CDK4/6 inhibitors palbociclib, ribociclib, and alpelisib in Phase 1/2 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive human epidermal growth factor receptor 2-negative breast cancer, as well as develops OPERA-01 for the of ER+/HER2- advanced or metastatic breast cancer.